Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-111 motion sickness crossover study in healthy volunteers
NL-OMON46445Phase 2Active, not recruiting
- Sponsor
- Sensorion
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seliforant in vertigo (4 arms), sponsored by Sensorion. Primary endpoint: Change from baseline in vigilance and tracking performance. Started Aug 2018; status: active, not recruiting.
02
Drugs
seliforant
03
Conditions
vertigo
Beyond the preview
Go deeper on NL-OMON46445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46445.